QBF ups Glycoz investment
Friday, 14 January, 2005
Queensland BioCapital Funds has invested a further $1.9 million in antibiotic-developer Glycoz, bringing its total stake in the company to $2.4 million
Glycoz is developing carbohydrate-based antibiotics based on research by Professors Mark von Itzstein and Ross Coppel.
The funding, in conjunction with a $1.8 million R&D Start Grant, will be used to take the company's lead compound through pre-clinical drug development.
QBF -- a $100 million closed end venture capital fund -- is a wholly-owned subsidiary of the Queensland Investment Corporation. It recently increased its holding in Brisbane unlisted biotech Xenome, taking up shares sold by Biotech Capital (ASX:BTC) and Cytopia (ASX:CTY).
In December, QIC's Neill Colledge replaced Kathryn Radford as CEO of QBF.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
